{"id":"NCT01377194","sponsor":"Forest Laboratories","briefTitle":"Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder","officialTitle":"A Double-blind, Placebo-Controlled, Fixed-Dose Study of Levomilnacipran SR in Patients With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-06","primaryCompletion":"2012-03","completion":"2012-03","firstPosted":"2011-06-21","resultsPosted":"2013-10-29","lastUpdate":"2013-10-29"},"enrollment":568,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"Levomilnacipran ER","otherNames":[]},{"type":"DRUG","name":"Levomilnacipran ER","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"EXPERIMENTAL"},{"label":"3","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER compared to placebo in patients with Major Depressive Disorder (MDD).","primaryOutcome":{"measure":"Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score - Mixed-effects Model for Repeated Measures (MMRM) Analysis.","timeFrame":"From Baseline to Week 8","effectByArm":[{"arm":"Placebo","deltaMin":-11.3,"sd":0.77},{"arm":"Levomilnacipran ER 40 mg","deltaMin":-14.6,"sd":0.79},{"arm":"Levomilnacipran ER 80 mg","deltaMin":-14.4,"sd":0.79}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0027"},{"comp":"OG000 vs OG002","p":"0.0043"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":51,"countries":["United States","Canada"]},"refs":{"pmids":["26644957","24144196"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":186},"commonTop":["Nausea","Headache","Dry mouth","Constipation","Upper respiratory tract infection"]}}